Bi-specific antibodies with high antigen-binding affinity identified by flow cytometry

Xu, Liming; Wang, Qiuying; Zhao, Juanjuan; Liu, Miao; Guo, Ming; Jiang, Yuanyuan; Cao, Hongwei; Li, Qingcui; Ren, Guangxin; Li, Deshan

doi:10.1016/j.intimp.2014.12.011

Cited by 7 publications

(2 citation statements)

References 32 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another interesting therapeutic tactic in this context is using bi-specific antibodies (BsAbs), which can bind to two types of epitopes ( 196 ). The clinical assessment of bsAbs in autoimmune diseases is in progress, with both achievements (phase II trials of obexelimab in systemic lupus erythematosus) and failures (phase II trials of lutikizumab in OA and romilkimab in IPF) ( 197 , 198 ).…”

Section: Clinical Implications and Therapeutic Perspectivesmentioning

confidence: 99%

Harmonizing hope: navigating the osteoarthritis melody through the CCL2/CCR2 axis for innovative therapeutic avenues

Abbasifard,

Khorramdelazad

2024

Front. Immunol.

View full text Add to dashboard Cite

Osteoarthritis (OA) is characterized by a complex interplay of molecular signals orchestrated by the CCL2/CCR2 axis. The pathogenesis of OA has been revealed to be influenced by a multifaceted effect of CCL2/CCR2 signaling on inflammation, cartilage degradation, and joint homeostasis. The CCL2/CCR2 axis promotes immune cell recruitment and tips the balance toward degeneration by influencing chondrocyte behavior. Insights into these intricate pathways will offer novel therapeutic approaches, paving the way for targeted interventions that may redefine OA management in the future. This review article explores the molecular symphony through the lens of the CCL2/CCR2 axis, providing a harmonious blend of current knowledge and future directions on OA treatment. Furthermore, in this study, through a meticulous review of recent research, the key players and molecular mechanisms that amplify the catabolic cascade within the joint microenvironment are identified, and therapeutic approaches to targeting the CCL2/CCR axis are discussed.

show abstract

Section: Clinical Implications and Therapeutic Perspectivesmentioning

confidence: 99%

Harmonizing hope: navigating the osteoarthritis melody through the CCL2/CCR2 axis for innovative therapeutic avenues

Abbasifard,

Khorramdelazad

2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Bispecific antibodies (bsAbs) are antibodies that can bind to two different types of epitopes so that they can be used for different signaling (8). Bispecific antibodies can be produced by three different processes, which are; chemical conjugation, fusion of two different hybridoma lines and through recombinant DNA utilization with a genetic approach.…”

Section: Bispecific Antibodiesmentioning

confidence: 99%

IL-17/TNF-α BISPECIFIC ANTIBODIES AS NEW THERAPEUTIC APPROACH TO RHEUMATOID ARTHRITIS

Adnan¹

2020

tmsj

View full text Add to dashboard Cite

Rheumatoid arthritis is a systemic autoimmune disease characterized by chronic inflammation causing swelling in the joints. IL-17/TNF-α bispecific antibodies are antibodies that can bind to two different types of epitopes and work on two different types of receptors. IL-17/TNF-α bispecific antibodies have anti-inflammatory effects that act by blocking the inflammatory pathways of rheumatoid arthritis. Thus, bispecific antibodies have the potential to be the latest effective therapy against rheumatoid arthritis.

show abstract

High throughput screening of recombinant antibodies against infectious hematopoietic necrosis virus from a combinatorial antibody library

Zhao

Miao

et al. 2016

Aquaculture

View full text Add to dashboard Cite

Bi-specific antibodies with high antigen-binding affinity identified by flow cytometry

Cited by 7 publications

References 32 publications

Harmonizing hope: navigating the osteoarthritis melody through the CCL2/CCR2 axis for innovative therapeutic avenues

Harmonizing hope: navigating the osteoarthritis melody through the CCL2/CCR2 axis for innovative therapeutic avenues

IL-17/TNF-α BISPECIFIC ANTIBODIES AS NEW THERAPEUTIC APPROACH TO RHEUMATOID ARTHRITIS

High throughput screening of recombinant antibodies against infectious hematopoietic necrosis virus from a combinatorial antibody library

Contact Info

Product

Resources

About